BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gorecki L, Andrs M, Korabecny J. Clinical Candidates Targeting the ATR-CHK1-WEE1 Axis in Cancer. Cancers (Basel) 2021;13:795. [PMID: 33672884 DOI: 10.3390/cancers13040795] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Singh DD, Parveen A, Yadav DK. Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance. Biomedicines 2021;9:1512. [PMID: 34829741 DOI: 10.3390/biomedicines9111512] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 van Harten AM, Brakenhoff RH. Targeted Treatment of Head and Neck (Pre)Cancer: Preclinical Target Identification and Development of Novel Therapeutic Applications. Cancers (Basel) 2021;13:2774. [PMID: 34204886 DOI: 10.3390/cancers13112774] [Reference Citation Analysis]
3 Tomasini PP, Guecheva TN, Leguisamo NM, Péricart S, Brunac AC, Hoffmann JS, Saffi J. Analyzing the Opportunities to Target DNA Double-Strand Breaks Repair and Replicative Stress Responses to Improve Therapeutic Index of Colorectal Cancer. Cancers (Basel) 2021;13:3130. [PMID: 34201502 DOI: 10.3390/cancers13133130] [Reference Citation Analysis]
4 Goehring L, Huang TT. WEE1i-ATRi combination therapy: a promising low-dose treatment for CCNE1-amplified gynecologic cancers. Cell Rep Med 2021;2:100402. [PMID: 34622238 DOI: 10.1016/j.xcrm.2021.100402] [Reference Citation Analysis]
5 Chu CN, Lee TKW. Targeting protein kinases in cancer stem cells. Essays Biochem 2022:EBC20220002. [PMID: 35607921 DOI: 10.1042/EBC20220002] [Reference Citation Analysis]
6 Di Franco S, Parrino B, Gaggianesi M, Pantina VD, Bianca P, Nicotra A, Mangiapane LR, Lo Iacono M, Ganduscio G, Veschi V, Brancato OR, Glaviano A, Turdo A, Pillitteri I, Colarossi L, Cascioferro S, Carbone D, Pecoraro C, Fiori ME, De Maria R, Todaro M, Screpanti I, Cirrincione G, Diana P, Stassi G. CHK1 inhibitor sensitizes resistant colorectal cancer stem cells to nortopsentin. iScience 2021;24:102664. [PMID: 34169240 DOI: 10.1016/j.isci.2021.102664] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Biegała Ł, Gajek A, Marczak A, Rogalska A. PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway. Biochim Biophys Acta Rev Cancer 2021;1876:188633. [PMID: 34619333 DOI: 10.1016/j.bbcan.2021.188633] [Reference Citation Analysis]
8 Maresca L, Stecca B, Carrassa L. Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment. Cells 2022;11:1466. [DOI: 10.3390/cells11091466] [Reference Citation Analysis]
9 Zhang S, Carlsen L, Hernandez Borrero L, Seyhan AA, Tian X, El-deiry WS. Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer. Biomolecules 2022;12:548. [DOI: 10.3390/biom12040548] [Reference Citation Analysis]
10 Pokhrel N, Genin O, Sela-donenfeld D, Cinnamon Y. HREM, RNAseq and Cell Cycle Analyses Reveal the Role of the G2/M-Regulatory Protein, WEE1, on the Survivability of Chicken Embryos during Diapause. Biomedicines 2022;10:779. [DOI: 10.3390/biomedicines10040779] [Reference Citation Analysis]
11 Yang M, Wang C, Zhou M, Bao L, Wang Y, Kumar A, Xing C, Luo W, Wang Y. KDM6B promotes PARthanatos via suppression of O6-methylguanine DNA methyltransferase repair and sustained checkpoint response. Nucleic Acids Res 2022:gkac471. [PMID: 35648484 DOI: 10.1093/nar/gkac471] [Reference Citation Analysis]
12 Hayashi R, Inomata M. Small cell lung cancer; recent advances of its biology and therapeutic perspective. Respir Investig 2021:S2212-5345(21)00193-3. [PMID: 34896039 DOI: 10.1016/j.resinv.2021.10.008] [Reference Citation Analysis]
13 Wilson DM, Duncton MAJ, Chang C, Lee Luo C, Georgiadis TM, Pellicena P, Deacon AM, Gao Y, Das D. Early Drug Discovery and Development of Novel Cancer Therapeutics Targeting DNA Polymerase Eta (POLH). Front Oncol 2021;11:778925. [PMID: 34900730 DOI: 10.3389/fonc.2021.778925] [Reference Citation Analysis]
14 Gupta N, Huang T, Horibata S, Lee J. Cell Cycle Checkpoints and Beyond: Exploiting the ATR/CHK1/WEE1 Pathway for the Treatment of PARP Inhibitor–Resistant Cancer. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106162] [Reference Citation Analysis]
15 Parsels LA, Zhang Q, Karnak D, Parsels JD, Lam K, Willers H, Green MD, Rehemtulla A, Lawrence TS, Morgan MA. Translation of DNA Damage Response Inhibitors as Chemoradiation Sensitizers From the Laboratory to the Clinic. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)02621-3. [PMID: 34348175 DOI: 10.1016/j.ijrobp.2021.07.1708] [Reference Citation Analysis]
16 Bothou C, Sharma A, Oo A, Kim B, Perge P, Igaz P, Ronchi CL, Shapiro I, Hantel C. Novel Insights into the Molecular Regulation of Ribonucleotide Reductase in Adrenocortical Carcinoma Treatment. Cancers (Basel) 2021;13:4200. [PMID: 34439352 DOI: 10.3390/cancers13164200] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]